ArticleInternational journal of women's health2025
Metastatic Brain Adenocarcinoma and Pelvic Squamous Carcinoma Originating From Cervical Adenosquamous Carcinoma: A Case Report and Literature Review.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical adenosquamous carcinoma (ASC) has a poor prognosis, and brain metastasis (BM) is extremely rare. Patients with BM have a poor prognosis. At present, there is no satisfactory treatment and no standard effective treatment. In recent years, immune checkpoint inhibitors (ICIs) and surgical treatment have emerged as a promising treatment for recurrent and metastatic cervical cancer (CC). Case: We report a 39-year-old CC patient whose cervical biopsy pathology showed adenocarcinoma with stage IIIC1r, and so underwent radical radiotherapy and chemotherapy 7 years ago. She was under a palliative enterostomy 4 years ago after intestinal perforation due to multiple recurrence of pelvic tumor. To our surprise, postoperative histopathology was squamous cell carcinoma and adenocarcinoma, ASC was confirmed. The postoperative efficacy of intravenous chemotherapy combined with immunotherapy was partial response (PR), and the efficacy of immunomaintenance therapy was progressive disease (PD). While she had gone through the recurrence of intestinal leakage 3 years ago, Pelvic exenteration (PE) was performed (postoperative histopathology squamous cell carcinoma), the postoperative effect was complete response (CR), and the patient selected regular reexamination. Isolated BM focus was developed in August 2024, and radiotherapy, chemotherapy and immunotherapy were refused after surgical treatment (postoperative histopathology adenocarcinoma). The progression-free survival (PFS) after BM is nearly one year. At present, the patient's reexamination showed no obvious abnormality. Conclusion: We report a case of ASC, whose at the initial treatment, the cervical lesions were mainly adenocarcinoma. However, pelvic metastatic lesion was mainly squamous carcinoma and underwent chemotherapy combined with immunotherapy combined with PE. The histopathology form of BM is adenocarcinoma. The surgical treatment has achieved remarkable curative effect and survival benefit.The choice of treatment is often based on the number of metastases in the patient's clinical state, tumor size, and metastases in other organs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.